Research
Hormonal
Incretin-based therapies improve cardiovascular risk factors (lipids, blood pressure) and reduce the risk of major cardiovascular events and heart failure in individuals with obesity.
For those with obesity, incretin therapies like semaglutide offer cardiovascular protection, lowering risks of heart events and heart failure, independent of just weight loss.
StrongSupportsVERY_HIGH confidence
In line with evidence accrued in patients with T2D, incretin-based therapies produced a favorable effect on traditional cardiovascular risk factors, such as lipids and blood pressure, and even reduced the risk of major cardiovascular events and heart failure-related events in individuals with obesity, as recently demonstrated for the first time in the SELECT trial with semaglutide 2.4 mg once-weekly.
Why this rating
Supported by RCTs and the SELECT trial.
Source
Incretin-based therapies for the treatment of obesity-related diseases
Irene Caruso et al. · npj Metabolic Health and Disease · 2024
narrative_reviewCited 30×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →